Commentary on 'The DOPPS practice monitor for US dialysis care: Update on trends in anemia management 2 years into the bundle': Iron(y) abounds 2 years later

摘要

The Centers for Medicare and Medicaid Services (CMS) enacted the end-stage renal disease (ESRD) Prospective Payment System (PPS) in January 2011. This updated reimbursement policy for ESRD services expanded capitated payments to include many previously separately billable items, most notably erythropoiesis-stimulating agents (ESAs) but also intravenous (IV) iron preparations. Consistent with all capitated systems, the ESRD PPS provides a strong financial incentive to reduce utilization of items that have high cost or large budget impact. Accordingly, most capitated systems, whether covering the general population or dialysis patients, include benchmarks to promote at least a minimum level of care.